SEC
NTLA icon

Seven Eight Capital’s Intellia Therapeutics NTLA Stock Holding History

Seven Eight Capital’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-32,279
Closed -$663K – 421
2024
Q3 		$663K Sell
32,279
-24,134
-43% -$556K 0.06% 506
2024
Q2 		$1.26M Buy
+56,413
New +$1.34M 0.13% 270
2024
Q1 		– Sell
-61,192
Closed -$1.87M – 750
2023
Q4 		$1.87M Buy
61,192
+42,034
+219% +$1.21M 0.22% 137
2023
Q3 		$606K Buy
19,158
+7,549
+65% +$293K 0.07% 352
2023
Q2 		$473K Buy
+11,609
New +$471K 0.08% 323
2023
Q1 		– Sell
-13,464
Closed -$470K – 556
2022
Q4 		$470K Buy
+13,464
New +$640K 0.12% 234

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Seven Eight Capital's NTLA Position: Q4 2024 in Review

Seven Eight Capital sold out of Intellia Therapeutics (NTLA) in Q4 2024, closing a stake of 32,279 shares — an estimated $663K sold.

Seven Eight Capital first reported a position in NTLA in Q4 2022 and held it in 6 quarters. The position peaked at $1.87M in Q4 2023. 294 funds tracked by Wall St. Rank hold NTLA as of Q4 2024.

  • Seven Eight Capital reported no remaining Intellia Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Seven Eight Capital sold 32,279 Intellia Therapeutics shares in Q4 2024, an estimated $663K.
  • Seven Eight Capital first reported a position in Intellia Therapeutics in Q4 2022 and held it in 6 quarters.
  • Seven Eight Capital's Intellia Therapeutics position peaked at $1.87M in Q4 2023.
  • 294 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2024.

Based on Seven Eight Capital's 13F filing for Q4 2024.